🧪
hypothesis

A tau PTM barcode gates trans-synaptic templating

Hypothesis

A tau PTM barcode gates trans-synaptic templating

Specific combinations of tau phosphorylation, acetylation, and truncation mark assemblies that evade degradation and template after synaptic transfer.
🧬 MAPT🩺 neurodegeneration🎯 Composite 74%💱 $0.60▼25.1%proposed
EvidenceStrong (63%)📖 7 cit🗣 1 debates 7 support 2 oppose
✓ All Quality Gates Passed
🏆 ChallengeResolve: tau PTM barcode controls seed-competent trans-synaptic templating$750K →
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite74%

🧪 Overview

Specific combinations of tau phosphorylation, acetylation, and truncation mark assemblies that evade degradation and template after synaptic transfer. Altering the PTM barcode should convert seed-competent tau into transferable but weakly pathogenic tau.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
A["MAPT tau protein"] -->|"phosphorylation, acetylation, truncation"| B["Combined PTM barcode"]
C["CDK5, GSK3B kinases"] -->|"hyperphosphorylation"| A
D["p300, CREBBP acetyltransferases"] -->|"acetylation"| A
E["Caspases, Calpains"] -->|"truncation"| A
B -->|"specific PTM pattern"| F["Seed-competent tau assemblies"]
F -->|"resistant to clearance"| G["Evasion of proteostasis"]
G -->|"enhanced stability"| F
F -->|"packaged in vesicles"| H["Exosome release"]
H -->|"intercellular transport"| I["Trans-synaptic transfer"]
I -->|"propagation of misfolding"| J["Templating of native tau"]
J -->|"spreading of pathology"| K["Neurodegeneration"]
K -->|"neuronal loss"| L["Cognitive decline"]
M["PTM barcode modification"] -.->|"restores degradability"| G
M -.->|"reduces seed competency"| F
N["Kinase inhibitors"] -->|"target upstream PTMs"| M
O["Deacetylase activation"] -->|"alters acetylation marks"| M

⚖️ Evidence

⚖️ Evidence Matrix5 supports1 contradicts
Supports
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Lab Invest2019PMID:30742061
Supports
Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.
Cold Spring Harb Perspect Med2017PMID:27940599medium
Supports
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nat Med2023PMID:37095250medium
Supports
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.
Nat Struct Mol Biol2025PMID:40044789medium
Supports
Isoform-specific patterns of tau burden and neuronal degeneration in MAPT-associated frontotemporal lobar degeneration.
Acta Neuropathol2022PMID:36066634medium
Contradicts
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
Cell2019PMID:31564456
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — MAPT

🧬 PDB 5O3L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for MAPT from GTEx v10.

Cerebellum209 Cerebellar Hemisphere199 Cortex152 Frontal Cortex BA9146 Anterior cingulate cortex BA24101 Hypothalamus86.4 Amygdala73.5 Nucleus accumbens basal ganglia72.2 Hippocampus72.1 Caudate basal ganglia64.7 Putamen basal ganglia58.1 Substantia nigra56.8 Spinal cord cervical c-149.2median TPM (GTEx v10)

💉 Clinical Trials (5)Relevance: 82%

0
Active
0
Completed
0
Total Enrolled
PHASE1
Highest Phase
Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through ExerciseNA
COMPLETED·NCT06584656 · Universidad de Granada
Healthy Aging Cognitive Function 1, Social Cerebrovascular Circulation
Aerobic exercise condition Resistance exercise condition
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's DiseasePHASE1
COMPLETED·NCT01850238 · Axon Neuroscience SE
Alzheimer Disease
AADvac1 Placebo
Genetic Studies of Early-onset DementiaUnknown
RECRUITING·NCT04906863 · Columbia University
Dementia, Early Onset
Blood draw Neurocognitive testing Medical questionnaire
Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's DiseasePHASE1
COMPLETED·NCT04413344 · Kyoto University
Familial Alzheimer Disease (FAD) PSEN1 Mutation
Bromocriptine Mesilate Placebos
Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal InterventionNA
COMPLETED·NCT03978052 · Parc de Salut Mar
Alzheimer Disease Cognitive Decline
EGCG Placebo EGCG Healthy lifestyle recommendations

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPT →

No DepMap CRISPR Chronos data found for MAPT.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 1.8%
Volatility
Low
0.0036
Events (7d)
5
Price History
▼25.1%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

View on SciDEX ↗